Study Phase 3

A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy

Trial Information

Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaMuscle, Bone, and Cartilage DiseasesEnrollment279% Female17%% White98%
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberC0168T51Data PartnerJohnson & JohnsonCondition StudiedSpondylitis, Ankylosing (Nonradiographic Axial)Mean/Median Age (Years)40

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.